Monday, November 18, 2013
Although Polar Capital is
launching its open-ended global biotech fund at a time when the sector is
riding high, fund manager David Pinniger said he intends to adjust the
beta of the fund's portfolio to make it attractive in any environment.
"This is a sector
investors should be investing in for the long term. They need to be confident
they can allocate capital to it irrespective of what the market is doing,"